Aortic Aneurysm Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Abdominal aortic aneurysm (AAA) refers to permanent dilation of the infrarenal aorta to 3 cm or more; surgical repair is indicated when the diameter reaches 5.5 cm or greater in men, 5.0 cm or greater in women, or when the aneurysm grows faster than 1 cm per year. Two principal repair strategies exist. Open surgical repair (OSR) involves a midline laparotomy or retroperitoneal approach, aortic cross-clamping, resection of the aneurysmal segment, and replacement with a prosthetic Dacron graft sutured in-place. Endovascular aneurysm repair (EVAR) deploys a bifurcated stent-graft via bilateral femoral artery access under fluoroscopic guidance, sealing the aneurysm from systemic blood pressure without aortic cross-clamping. EVAR now accounts for over 75% of elective AAA repairs in high-income countries. Emergency repair is required for ruptured AAA, which carries 40–50% operative mortality even in hospital. Both approaches definitively prevent rupture when the aneurysm is successfully excluded, but differ substantially in perioperative risk, recovery, and long-term reintervention profile. Patient anatomy, age, comorbidities, and center experience guide the choice between EVAR and OSR. Contemporary imaging — CT angiography with 3D reconstruction, duplex ultrasound for surveillance, and IVUS intraoperatively — has refined anatomical assessment, device sizing, and endoleak detection. Patient anatomy, age, comorbidities, and centre experience guide the choice between EVAR and OSR in shared decision-making.

Repair is indicated for infrarenal AAA measuring 5.5 cm or greater in men and 5.0 cm or greater in women with acceptable operative risk. Rapidly expanding aneurysms, defined as growth exceeding 1 cm per year or more than 0.5 cm over six months, require repair regardless of absolute diameter. Symptomatic AAA presenting with back pain, flank pain, or tenderness without confirmed rupture is a semi-urgent indication. Ruptured AAA is a life-threatening emergency requiring immediate repair. Juxtarenal and pararenal AAA, where the aneurysm neck abuts or involves the renal arteries, may require fenestrated or branched EVAR or a more complex open repair. Thoracoabdominal aortic aneurysms (TAAA) involving visceral segment vessels are among the most complex cases managed surgically or with branched endovascular grafts. Concurrent iliac artery aneurysm, typically greater than 3.5 cm, is often treated in the same setting by extending the EVAR limbs to the external iliac arteries with internal iliac embolization. Mycotic aortic aneurysm from aortic infection is a rare but critical indication requiring debridement, antibiotic therapy, and usually open repair with antibiotic-impregnated or autologous conduit.

Elective EVAR eligibility requires a detailed CT angiography assessment of the aortic neck length (minimum 15 mm infrarenal), neck diameter (up to 32 mm), neck angulation (below 60 degrees), and iliac access vessel diameter (at least 7 mm). Severe neck thrombus, calcification, or angulation can preclude standard EVAR but may be addressed with fenestrated or chimney EVAR techniques at high-volume centers. OSR is preferred for young patients under 70 with favorable anatomy, as it avoids lifelong endoleak surveillance and offers better long-term durability. High-risk patients with significant cardiac, pulmonary, or renal comorbidities benefit from the reduced physiologic stress of EVAR. Preoperative cardiac evaluation, pulmonary function testing, and creatinine measurement with eGFR calculation are standard. Patients with baseline renal impairment require careful contrast volume management and may need CO2 angiography or IVUS-guided EVAR to minimize contrast nephropathy. Emergency EVAR for hemodynamically unstable ruptured AAA is feasible when anatomy is suitable; REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) may bridge the patient to definitive repair.

Two definitive treatment strategies exist for abdominal aortic aneurysm (AAA). Endovascular aneurysm repair (EVAR) is the predominant approach, performed under regional or general anaesthesia through bilateral femoral artery cut-downs or percutaneous access. A bifurcated stent-graft (Medtronic Endurant, Cook Zenith, Gore Excluder, Terumo Aorfix) is deployed under fluoroscopic guidance, with the proximal neck seal zone at least 15 mm below the renal arteries and distal limb seal in the common iliac arteries. Intraoperative completion angiography and cone-beam CT confirm seal and absence of endoleak. EVAR is performed as 1–2 night admission. Open surgical repair (OSR) via midline laparotomy or retroperitoneal approach involves aortic cross-clamping, aneurysm sac opening, placement of a knitted Dacron or polyester bifurcated graft sutured in an end-to-end fashion to the aortic neck proximally and iliac arteries distally, followed by sac closure over the graft. Cross-clamp time is 30–60 minutes. Fenestrated EVAR (fEVAR) and branched EVAR (bEVAR) extend endovascular repair to juxtarenal and pararenal aneurysms using custom-fabricated or off-the-shelf devices with fenestrations or branches for the renal arteries, superior mesenteric artery, and coeliac axis. Chimney/snorkel EVAR places parallel covered stents into the visceral arteries alongside the main aortic body. Hybrid approaches combine open visceral debranching with retrograde iliac graft reconstruction before EVAR deployment. Emergency endovascular repair (emergency EVAR) for ruptured AAA uses aortic balloon occlusion (REBOA) to temporise haemodynamics while completing graft deployment.

EVAR confers significantly lower perioperative mortality compared to open surgery. The DREAM and EVAR-1 trials documented EVAR perioperative mortality of 1.2–1.7% versus 4.6–4.7% for OSR. Major 30-day complication rates are 3–5% for EVAR versus 10–15% for OSR. Hospital stay averages 1–3 days following EVAR versus 7–10 days for OSR. Estimated blood loss with EVAR is 200–500 mL, compared to 1,000–2,500 mL with open repair, significantly reducing transfusion requirements. ICU admission after EVAR is rare, whereas OSR typically requires 1–2 days of critical care monitoring. The OVER (Veterans Affairs OPEN vs EVAR) trial at 9-year follow-up showed equivalent all-cause mortality between approaches, confirming that EVAR's early survival advantage is maintained but not extended long-term. Return to normal activity after EVAR is 2–4 weeks versus 6–8 weeks for open surgery. Rupture prevention is definitive with either approach when the aneurysm is fully excluded, eliminating the 80% mortality associated with untreated rupture at 5.5 cm threshold.

EVAR introduces procedure-specific complications not seen with OSR. Endoleak—continued perfusion of the aneurysm sac outside the stent-graft—is the most important EVAR-specific complication. Type I endoleak (proximal or distal seal failure, 2–5%) requires prompt reintervention. Type II endoleak (back-flow from lumbar or inferior mesenteric artery, 15–25%) is usually benign but requires monitoring for sac expansion. Type III (graft junction failure) and Type IV (fabric porosity) are rare. Device migration (2–5% at 5 years) and limb occlusion (1–3%) require secondary procedures. EVAR carries a 10–15% reintervention rate at 5 years versus 3–5% for OSR. Lifelong annual CT surveillance is mandatory to detect endoleak and sac growth. Post-implantation syndrome—fever and elevated inflammatory markers—occurs in 30–50% of patients and is self-limiting. Open surgical risks include aortic cross-clamp cardiac stress (MI risk 2–4%), renal ischemia, bowel ischemia from inferior mesenteric artery sacrifice, and sexual dysfunction from retrograde ejaculation in 5–10% of men. Spinal cord ischemia is more relevant for thoracoabdominal repairs. Ruptured AAA carries 40–50% operative mortality even with immediate surgical attention.

EVAR mandates lifelong surveillance to detect endoleak, device migration, sac expansion, and limb occlusion. Standard protocol: CT angiography at 1 month, 6 months, and 12 months post-EVAR, then annually. If three consecutive imaging studies confirm complete exclusion without sac growth, many centres transition to duplex ultrasound surveillance to reduce radiation and contrast exposure. Sac diameter monitoring is the critical endpoint — stable or shrinking sac indicates successful exclusion; sac growth over 5 mm triggers investigation for previously undetected endoleak or device failure. Type II endoleaks with sac growth require selective embolisation of the feeding vessel (lumbar or inferior mesenteric artery) via translumbar or transcaval approach. After open surgical repair, CT surveillance at 5 years is generally sufficient as structural graft failure is uncommon, though anastomotic pseudoaneurysm, graft limb occlusion, and aortoenteric fistula remain long-term concerns. All patients receive aspirin and statin therapy indefinitely. Blood pressure optimisation (target below 130/80 mmHg), smoking cessation counselling, and diabetes management are standard secondary prevention. Patients should carry an implant card documenting the stent-graft device model and serial number.

Aortic aneurysm repair costs vary widely based on approach (EVAR vs OSR), device costs, and healthcare system. In India, EVAR ranges from USD 10,000–25,000 and open surgical repair from USD 6,000–14,000 at JCI-accredited centers in Delhi, Mumbai, Chennai, and Hyderabad. Thailand offers EVAR at USD 15,000–35,000 in centers like Bumrungrad International and Bangkok Hospital. Turkey provides competitive pricing at USD 10,000–25,000 for EVAR at Istanbul centers. Germany charges EUR 20,000–50,000 for EVAR procedures in university hospitals. In the United States, EVAR costs USD 35,000–80,000 and OSR USD 25,000–60,000, driven by device pricing (stent-graft alone costs USD 10,000–20,000) and hospital facility fees. Singapore prices EVAR at USD 28,000–60,000 at National Heart Centre or Mount Elizabeth Hospital. The United Kingdom provides both approaches on the NHS at no direct cost to eligible patients. Medical tourism to India or Thailand offers savings of 60–80% compared to US prices for comparable surgical expertise and accredited facilities. Patients should also factor in EVAR's ongoing annual surveillance CT costs (USD 500–1,500 per year) when comparing long-term financial burden.

For aneurysms below the repair threshold (under 5.5 cm in men, under 5.0 cm in women), surveillance is the appropriate management: abdominal aortic ultrasound every 6–12 months depending on size (3–3.9 cm: annually; 4–4.9 cm: every 6 months; 5–5.4 cm: every 3 months). The UK Small Aneurysm Trial and ADAM trial demonstrated no mortality benefit from immediate repair versus surveillance for asymptomatic aneurysms below this threshold. Medical optimisation — including smoking cessation, statin therapy (which may slow aneurysm expansion by 1–2 mm/year), ACE inhibitor/ARB therapy, and antiplatelet therapy — is essential during surveillance. Doxycycline (matrix metalloproteinase inhibitor) showed modest benefit in reducing expansion rate in small trials but is not routinely recommended pending larger data. Endovascular repair under local anaesthesia with conscious sedation is feasible for very high surgical risk patients who are not candidates for general anaesthesia, expanding EVAR eligibility. Palliative management without repair is appropriate in patients with very poor prognosis from comorbid illness, where repair risk-benefit ratio is unfavourable. Surgical lifestyle modification (dietary change, weight loss) does not shrink existing aneurysms but may slow progression.